Article

Erick Gaussens

Author(s):

Erick Gaussens

Erick Gaussens is Chief Scientific Officer at ProductLife Group

www.productlifegroup.com

egaussens@productlife-group.com

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Pharmaceutical Executive
Pharmaceutical Executive
Related Content
Stock.adobe.com
October 2nd 2025

Vanda Pharmaceuticals and FDA Agree on Collaborative Framework for Resolution of Disputes over Hetlioz and Tradipitant

Nicholas Jacobus
Pharmaceutical Executive
October 2nd 2025

Pharmaceutical Executive Daily: Novo Nordisk Resubmits BLA for Awiqli

Nicholas Jacobus
President Donald Trump
October 2nd 2025

Trump Pauses Plans to Impose 100% Tariffs on Pharma: Report

Mike Hollan
Pharmaceutical Executive
October 2nd 2025

Pharmaceutical Executive Daily: September 29, 2025

Nicholas Jacobus
How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proactive CMC Strategies
October 2nd 2025

How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proactive CMC Strategies

Louis Cicchini, PhD, and Michael Day, PhD
Stock.adobe.com
October 2nd 2025

Novartis’ Chronic Spontaneous Urticaria Treatment Rhapsido Receives FDA Approval

Nicholas Jacobus
© 2025 MJH Life Sciences

All rights reserved.